Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: Case-control study

BMJ (Online)

Volumn 345, Issue 7869, 2012, Pages

  Menne, Jan ^a   Nitschke, Martin ^b   Stingele, Robert ^c   Abu Tair, Mariam ^d   Beneke, Jan ^a   Bramstedt, Jörn ^e   Bremer, Jan P ^f   Brunkhorst, Reinhard ^g   Busch, Veit ^h   Dengler, Reinhard ^a   Deuschl, Günther ^c   Fellermann, Klaus ^b   Fickenscher, Helmut ^c   Gerigk, Christoph ⁱ   Goettsche, Alexander ^c   Greeve, Jobst ^j   Hafer, Carsten ^a   Hagenmüller, Friedrich ^f   Haller, Hermann ^a   Herget Rosenthal, Stefan ^k   Hertenstein, Bernd ^l   Hofmann, Christina ^b   Lang, Melanie ^m   Kielstein, Jan T ^a   Klostermeier, Ulrich C ^c   Knobloch, Johannes ^b   Kuehbacher, Markus ⁿ   Kunzendorf, Ulrich ^c   Lehnert, Hendrik ^b   Manns, Michael P ^a   Menne, Tobias F ^o   Meyer, Tobias N ^m   Michael, Claus ^a   Münte, Thomas ^b   Neumann Grutzeck, Christine ^f   Nuernberger, Jens ^p   Pavenstaedt, Hermann ^h   Ramazan, Leyla ^a   Renders, Lutz ^c   Repenthin, Jonas ^m   Ries, Wolfgang ^q   Rohr, Axel ^c   Rump, Lars Christian ^r   Samuelsson, Ola ^s   Sayk, Friedhelm ^b   Schmidt, Bernhard M W ^a   Schnatter, Sabine ^t   Schöcklmann, Harald ^c   Schreiber, Stefan ^c   Von Seydewitz, Cay U ^f   Steinhoff, Jürgen ^b   Stracke, Sylvia ^u   Suerbaum, Sebastian ^a   Van De Loo, Andreas ⁱ   Vischedyk, Martin ^j   Weissenborn, Karin ^a   Wellhöner, Peter ^b   Wiesner, Monika ^v   Zeissig, Sebastian ^c   Büning, Jürgen ^b   Schiffer, Mario ^a   Kuehbacher, Tanja ^c   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d EVANGELISCHES KRANKENHAUS   (Germany)

^e Bremerhaven Reinkenheide Hospital   (Germany)

^f Asklepios Hospital Hamburg Altona   (Germany)

^g Hannover Hospital   (Germany)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ Marienhospital Hamburg   (Germany)

^j St Vincenz Hospital   (Germany)

^k Red Cross Hospital Bremen   (Germany)

^l Hospital Bremen Mitte   (Germany)

^m Asklepios Klinikum Hamburg Barmbek   (Germany)

ⁿ UNIVERSITY OF HAGEN   (Germany)

^o FREEMAN HOSPITAL   (United Kingdom)

^p HELIOS KLINIKEN SCHWERIN   (Germany)

^q Diakonissenkrankenhaus Flensburg   (Germany)

^r HEINRICH HEINE UNIVERSITY   (Germany)

^s SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^t Ernst von Bergmann Clinic   (Germany)

^u UNIVERSITY OF GREIFSWALD   (Germany)

^v KLINIKUM OLDENBURG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CREATININE; ECULIZUMAB; FRESH FROZEN PLASMA; HEMOGLOBIN; LACTATE DEHYDROGENASE; MEROPENEM; PREDNISOLONE; PREDNISONE; RIFAXIMIN; ANTIINFECTIVE AGENT; GLUCOCORTICOID; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ABDOMINAL SURGERY; ADULT; ARTICLE; ARTIFICIAL VENTILATION; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ENTEROHEMORRHAGIC ESCHERICHIA COLI; FEMALE; GERMANY; HEMOLYTIC UREMIC SYNDROME; HUMAN; INTESTINE NECROSIS; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PLASMAPHERESIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SEIZURE; TREATMENT OUTCOME; ADOLESCENT; AGED; ANIMAL; BLOOD; CHILD; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG COMBINATION; EPIDEMIC; ESCHERICHIA COLI INFECTION; INFANT; METHODOLOGY; MICROBIOLOGY; MIDDLE AGED; MOUSE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; THROMBOCYTE COUNT; UTILIZATION REVIEW; VALIDATION STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CASE-CONTROL STUDIES; CHILD; COMBINED MODALITY THERAPY; DIARRHEA; DISEASE OUTBREAKS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GERMANY; GLUCOCORTICOIDS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOLOGIC FACTORS; INFANT; L-LACTATE DEHYDROGENASE; MALE; MICE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMAPHERESIS; PLATELET COUNT; RENAL DIALYSIS; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864876679     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e4565     Document Type: Article

References (35)

1. Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, et al. Epidemic profile of shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011;365:1771-80.
2. Robert Koch Institut. Abschließende Darstellung und Bewertung der epidemiologischen Erkenntnisse im EHEC O104:H4 Ausbruch. 2011. [Final report on the epidemiology of the EHEC O104-H4 outbreak, Germany 2011.] www.rki.de/cln-117/nn-205760/DE/Content/InfAZ/E/EHEC/EHEC-Abschlussbericht, templateId=raw,property=publicationFile.pdf/EHECAbschlussbericht.pdf.
3. Dundas S, Todd WT, Stewart AI, Murdoch PS, Chaudhuri AK, Hutchinson SJ. The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 2001;33:923-31. (Pubitemid 32907091)
4. Wood R, Donaghy M, Dundas S. Monitoring patients in the community with suspected Escherichia coli O157 infection during a large outbreak in Scotland in 1996. Epidemiol Infect 2001;127:413-20. (Pubitemid 34092787)
5. Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005;365:1073-86. (Pubitemid 40386785)
6. Bell BP, Goldoft M, Griffin PM, Davis MA, Gordon DC, Tarr PI, et al. A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA 1994;272:1349-53.
7. Mellmann A, Harmsen D, Cummings CA, Zentz EB, Leopold SR, Rico A, et al. Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing technology. PLoS One 2011;6:e22751.
8. Bielaszewska M, Mellmann A, Zhang W, Kock R, Fruth A, Bauwens A, et al. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis 2011;11:671-6.
9. Rasko DA, Webster DR, Sahl JW, Bashir A, Boisen N, Scheutz F, et al. Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 2011;365:709-17.
10. Rohde H, Qin J, Cui Y, Li D, Loman NJ, Hentschke M, et al. Open-source genomic analysis of shiga-toxin-producing E. coli O104:H4. N Engl J Med 2011;365:718-24.
11. Denamur E. The 2011 shiga toxin-producing Escherichia coli O104:H4 German outbreak: a lesson in genomic plasticity. Clin Microbiol Infect 2011;17:1124-5.
12. Kemper MJ. Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective. Pediatr Nephrol 2012;27:161-4.
13. Pennington H. Escherichia coli O157. Lancet 2010;376:1428-35.
14. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, et al. Eculizumab in severe shiga-toxin-associated HUS. N Engl J Med 2011;364:2561-3.
15. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-43. (Pubitemid 44427447)
16. Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009;360:542-4.
17. Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009;4:1920-4.
18. Stahl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coliinduced hemolytic uremic syndrome. Blood 2011;117:5503-13.
19. Ducker C, Dautel P, Wagner K, Przewozna J, Oehlerking S, Repenthin J, et al. [Clinical symptoms, treatment and outcome of EHEC and EHEC-HUS patients treated as in-patients]. Dtsch Med Wochenschr 2011;136:1770-6.
20. Greinacher A, Friesecke S, Abel P, Dressel A, Stracke S, Fiene M, et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011;378:1166-73.
21. Magnus T, Rother J, Simova O, Meier-Cillien M, Repenthin J, Moller F, et al. The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. Brain 2012;135:1850-9.
22. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010;25:83-177.
23. Cornick NA, Jelacic S, Ciol MA, Tarr PI. Escherichia coli O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome. J Infect Dis 2002;186:57-63. (Pubitemid 34666914)
24. Chandler WL, Jelacic S, Boster DR, Ciol MA, Williams GD, Watkins SL, et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002;346:23-32. (Pubitemid 34438916)
25. Bambauer R, Latza R, Schiel R. Therapeutic apheresis in the treatment of hemolytic uremic syndrome in view of pathophysiological aspects. Ther Apher Dial 2011;15:10-9.
26. Colic E, Dieperink H, Titlestad K, Tepel M. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet 2011;378:1089-93.
27. Ruggenenti P, Remuzzi G. A German outbreak of haemolytic uraemic syndrome. Lancet 2011;378:1057-8.
28. German Society of Nephrology (DGfN). Therapeutische Apheresebehandlung bei EHEC assoziiertem HUS. [Therapeutic plasma exchange in EHEC-HUS.] 2011. www.dgfn.eu/aktuell/ehec-informationen/fuer-das-fachpublikum/ therapeutische-apheresebehandlung-bei-ehecassoziiertem-hus.html.
29. Perez N, Spizzirri F, Rahman R, Suarez A, Larrubia C, Lasarte P. Steroids in the hemolytic uremic syndrome. Pediatr Nephrol 1998;12:101-4. (Pubitemid 28165795)
30. Scheiring J, Rosales A, Zimmerhackl LB. Clinical practice. Today's understanding of the haemolytic uraemic syndrome. Eur J Pediatr 2010;169:7-13.
31. Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MK, Acheson DW. Quinolone antibiotics induce shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 2000;181:664-70. (Pubitemid 30131837)
32. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolyticuremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000;342:1930-6. (Pubitemid 30419087)
33. Rahal EA, Kazzi N, Kanbar A, Abdelnoor AM, Matar GM. Role of rifampicin in limiting Escherichia coli O157:H7 shiga-like toxin expression and enhancement of survival of infected BALB/c mice. Int J Antimicrob Agents 2011;37:135-9.
34. Nitschke M, Sayk F, Hartel C, Roseland RT, Hauswaldt S, Steinhoff J, et al. Association between azithromycin therapy and duration of bacterial shedding among patients with shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 2012;307:1046-52.
35. Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F, Mellmann A, et al. Epidemic Escherichia coli O104:H4: effects of antibiotics on shiga toxin 2 production and bacteriophage induction. Antimicrob Agents Chemother 2012;56:3277-82.